Arpad Simon, M.D., has been appointed to the role of vice president of pharmacovigilance at AMAG Pharmaceuticals. Dr. Simon will have responsibility for all pharmacovigilance functions at AMAG, including product safety surveillance, aggregate safety reporting and risk management. He will also oversee safety evaluation across the company’s clinical development activities and marketed therapeutics.
 
Dr. Simon has more than 20 years of pharmaceutical industry experience with extensive operational and leadership experience in clinical development and pharmacovigilance. He previously served in executive-level pharmacovigilance roles at Relypsa, Mitsubishi Tanabe Pharma, Pfizer.
 
Dr. Simon also worked for five years at the FDA Center for Drug Evaluation and Research. He has successfully led and managed initiatives in the areas of clinical trials, post-marketing safety, benefit-risk management, business development, integration, process design and regulatory interactions.
 
“Arpad’s vast experience in pharmacovigilance and risk management will be invaluable to AMAG as the company continues to expand. He understands how to build and successfully lead strong pharmacovigilance programs in growth-oriented environments. We are excited to have him join the team,” said Robert Kaper, M.D., senior vice president, medical and scientific affairs at AMAG.